寧科生物(600165.SH)：濟南長悦違約導致公司控股子公司中科新材臨時停產
格隆匯4月5日丨寧科生物(600165.SH)公佈，此前披露，公司於2022年11月16日召開第九屆董事會第七次會議，審議通過了《關於控股子公司增資暨公司放棄優先認購權的議案》，濟南長悦新材料科技產業合夥企業(有限合夥)(“濟南長悦”)以自有資金向寧夏中科生物新材料有限公司(“中科新材”)增資3億元，並於2022年11月17日完成工商變更登記手續。
公司於近日收到中科新材的通知，根據《寧夏中科生物新材料有限公司之增資協議》約定，濟南長悦對中科新材的增資款分三期實繳，無特殊情況下，最後一期增資款應於2023年3月31日前實繳。濟南長悦未如期如約履行價款支付義務，經中科新材屢次催吿，截止2023年3月31日，其仍未履行向中科新材增資3億元資本金的實繳義務。
此次中科新材增資主體濟南長悦未能按《增資協議》約定履行對中科新材3億元註冊資本金的實繳義務，構成實際違約，給公司造成以下不利影響：
(一)濟南長悦向中科新材增資款3億元未能如期實繳到位，致使中科新材流動資金不足，無法按原計劃組織生產；中科新材7000萬元的短期債務無法按期償還並已被債權人提起訴訟；石嘴山市正興成新材料技術合夥企業(有限合夥)剩餘股權轉讓款未能按期支付。
(二)根據《增資協議》約定，中科新材《公司章程》、註冊資本金、董事、監事人員已變更，並在《增資協議》中對首期認繳資金到位後中科新材的總經理、財務總監崗位人員進行預安排。因認繳的增資款未實繳到位，上述變動對公司及子公司的融資渠道，包括但不限於增資擴股、銀行借款造成嚴重阻礙。
濟南長悦此次違約已導致中科新材臨時停產，該事項目前尚未形成明確的解決方案，公司已在積極尋找多種方案改善中科新材現狀。如中科新材未能在3個月內恢復生產，公司存在被實施“其他風險警示(ST)”的風險。
目前，公司控股子公司寧夏華輝環保科技股份有限公司生產經營正常，中科新材臨時停產事宜，公司正在積極籌措，尋找融資渠道，儘快確定解決方案，預計在3個月內恢復生產。中科新材停產事項對公司當期業績的影響尚無法準確預計。對於濟南長悦的實際違約行為，中科新材將採取法律手段追償損失，維護公司及全體股東的合法權益。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
